Cholangiocarcinoma is a type of cancer that forms in the slender tubes (bile ducts) that carry the digestive fluid bile. The specific reason for the cause of cholangiocarcinoma is not known as of yet. The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural) and may sometimes affect gall bladder as well. The significant symptoms of cholangiocarcinoma includes jaundice, weight reduction, loss of hunger, blood in stool and urine, stomach pain, fever, and itching.
The global cholangiocarcinoma market is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8 % during the forecast period (2021-2028).
Figure 1.Global Cholangiocarcinoma Market Share (%) in Terms of Value, By Treatment Type, 2021
Increasing prevalence of cholangiocarcinoma is expected to drive the market growth during the forecast period.
Increasing prevalence of cholangiocarcinoma is expected to drive the global cholangiocarcinoma market growth over the forecast period. For instance, according to American Cancer Society’s 2018 report, around 8,000 people in the U.S. are diagnosed with cholangiocarcinoma to each year. This includes both intrahepatic (inside the liver) and extrahepatic (outside the liver) bile duct cancers.
Figure 2.Global Cholangiocarcinoma Market Share (%), By Distribution Channel, 2021
Key players operating in the global cholangiocarcinoma market are focusing on adoption of inorganic growth strategies such as acquisition which are expected to drive the market growth during the forecast period.
key companies are focusing on inorganic strategies such as acquisition in order to strengthen their products presence and this is expected to create a conductive environment for growth of the Cholangiocarcinoma market. For instance, in January 2021, Servier, a global pharmaceutical company, announced the acquisition of Agios Pharmaceuticals company’s commercial, clinical, and research-stage oncology portfolio which includes Tibsovo (ivosidenib tablets) for treatment of Cholangiocarcinoma and others.
|Base Year:||2020||Market Size in 2021:||US$ 185.4 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2020 to 2027|
|Forecast Period 2021 to 2028 CAGR:||12.8%||2027 Value Projection:||US$ $ 429.6 Mn|
Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc.
|Restraints & Challenges:||
Global Cholangiocarcinoma Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread over 100 countries across the globe and the World Health Organization had declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 143 million infected individuals worldwide as of April 21st 2021.
COVID-19 affects the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs. For instance, In April 2020, Chinese suppliers stopped supplies to India due to non-availability of labour, containers are piling up and all space is occupied. The incoming vessels will not be able to offload the containers and may bypass that result in the shortage of medicines in India.
Furthermore, players operating in the global cholangiocarcinoma market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges includes supply of raw materials (due to irregularities in transportation), which are required for manufacturing drug formulations. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life threatening disorders.
Global Cholangiocarcinoma Market: Restraint
The major factors that hinder growth of the global cholangiocarcinoma market includes high cost of cholangiocarcinoma and cancer treatments and the time-consuming approach for approving new drugs.
Major players operating in the global cholangiocarcinoma market are Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc.
Bile duct cancer is also called as cholangiocarcinoma. Cholangiocarcinoma is a form of cancer in which epithelial cells are mutated, which means the cells show characters of epithelial differentiation in the bile duct. The bile duct carries a fluid called bile, which is secreted in the liver and stored in the gall bladder. The essential function of bile is to breakdown the fats during digestion. Signs of bile duct cancer include jaundice and pain in the abdomen. There are two types of bile duct cancer intrahepatic bile duct cancer and extrahepatic bile duct cancer. Intrahepatic bile duct cancer occurs in the parts of the bile ducts within the liver. Extrahepatic bile duct cancer is a rare cancer that forms in the bile ducts outside the liver.
Key players operating in the global cholangiocarcinoma market are focusing on adoption of inorganic growth strategies such as collaborations, which are expected to drive the market growth during the forecast period. For instance, In March 2021, QED Therapeutics collaborated with Helsinn Group, is a privately-owned Swiss Pharma Company. The collaboration intends to co-develop and commercialize Infigratinib, an oral FGFR1-3 selective inhibitor, for patients dealing with cholangiocarcinoma (bile duct cancer). Moreover, In February 2019, Imbrium Therapeutics L.P., in collaboration with Mundipharma EDO GmbH, a part of the Mundipharma-network, announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to its investigational drug etoposide toniribate, a novel topoisomerase II inhibitor, for the treatment of relapsed refractory biliary tract cancer.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.